Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Molecular Partners AGMLLCF 34 Price-to-Tangible-Book is 2.10 as of Sep. 05, 2026. GuruFocus rates MLLCF with a GF Score™ of 34/100 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,131 Biotechnology companies, Molecular Partners AG ranks better than 65.69% on this metric.
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Molecular Partners AG Price-to-Tangible-Book Related Terms
Molecular Partners AG Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Molecular Partners AG's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Molecular Partners AG Price-to-Tangible-Book Chart
MLLCF vs VRTX, REGN, MRNA: Price-to-Tangible-Book Comparison
For the Biotechnology subindustry, Molecular Partners AG's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Molecular Partners AG Price-to-Tangible-Book vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Molecular Partners AG's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Molecular Partners AG's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Molecular Partners AG (MLLCF) has a Price-to-Tangible-Book of 2.10 as of Sep. 05, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Molecular Partners AG and its competitors. According to the industry distribution chart, Molecular Partners AG ranks #388 out of 1131 companies in the Biotechnology industry, placing it in the top 34.3%.
Is Molecular Partners AG's Price-to-Tangible-Book too high?
Molecular Partners AG's current Price-to-Tangible-Book is 2.10. The Biotechnology industry median Price-to-Tangible-Book is 3.26. Molecular Partners AG's value of 2.10 is 35.6% below this industry median. Based on the distribution chart, Molecular Partners AG ranks #388 out of 1131 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Molecular Partners AG has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Molecular Partners AG's Price-to-Tangible-Book compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Molecular Partners AG ranks #388 out of 1131 companies for Price-to-Tangible-Book. This puts Molecular Partners AG in the upper half of its industry. The industry median Price-to-Tangible-Book is 3.26. Molecular Partners AG's value of 2.10 is 35.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Biotechnology company?
The median Price-to-Tangible-Book among Biotechnology companies is 3.26, based on 1,131 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Molecular Partners AG's current Price-to-Tangible-Book of 2.10 is 35.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Molecular Partners AG and its competitors. For the Biotechnology industry, the median Price-to-Tangible-Book is 3.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Molecular Partners AG's current Price-to-Tangible-Book is 2.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Molecular Partners AG stock overvalued right now?
Based on GuruFocus' analysis, Molecular Partners AG (MLLCF) is currently considered Significantly Overvalued. The current Price-to-Tangible-Book is 2.10 and 35.6% below the Biotechnology industry median of 3.26. Molecular Partners AG's overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Molecular Partners AG (MLLCF), the current Price-to-Tangible-Book is 2.10 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
34GF Score
Get the complete analysis for MLLCF
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLLCF has been successfully added to your 
